<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01759485</url>
  </required_header>
  <id_info>
    <org_study_id>GMHC-VITD</org_study_id>
    <secondary_id>29-12</secondary_id>
    <nct_id>NCT01759485</nct_id>
  </id_info>
  <brief_title>Vitamin D for Schizophrenia</brief_title>
  <official_title>Vitamin D Supplementation as Adjunct to Clozapine-treated Chronic Schizophrenia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geha Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Geha Mental Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Despite improvements in medications, treatment delivery and rehabilitation,&#xD;
      schizophrenia outcomes remain suboptimal. There are a proportion of 30-40%&#xD;
      treatment-resistant schizophrenia patients. Multiple lines of evidence suggest that vitamin D&#xD;
      is a neuro-active steroid that acts on brain development, leading to alterations in brain&#xD;
      neurochemistry and adult brain function. Early deficiencies have been linked with&#xD;
      neuropsychiatric disorders, such as schizophrenia, and adult deficiencies have been&#xD;
      associated with adverse brain outcomes, including Parkinson's disease, Alzheimer's disease,&#xD;
      depression and cognitive decline. Ecological studies support a potential role for vitamin D&#xD;
      in schizophrenia. These data include studies that have explored the association between&#xD;
      schizophrenia and winter/spring birth and also the apparent increased incidence and&#xD;
      prevalence of schizophrenia at higher latitudes. Objective: To evaluate the effect of&#xD;
      vitamin-D supplementation on the mental state of clozapine-treated chronic schizophrenia&#xD;
      patients, and the relation of disease severity to serum vitamin D levels. Methods: the&#xD;
      investigators will use a prospective, interventional, longitudinal, double blinded,&#xD;
      placebo-controlled, randomized design. The investigators will recruit 50 clozapine-treated&#xD;
      chronic schizophrenia patients, with low level of serum vitamin-D, that will be randomly&#xD;
      assigned (1:1 ratio) to receive either weekly oral drops of vitamin D (Cholecalciferol) or&#xD;
      oral drops of placebo for 8 weeks follow-up. Repeated assessments will include: clinical&#xD;
      severity scales (PANSS, CGI), side effects (SAS, BARS, clozapine side effects), cognitive&#xD;
      (MoCA), metabolic parameters and laboratory data. Patients who were assigned to placebo will&#xD;
      be supplemented with vitamin D after the 8 weeks period, and then will be assessed again with&#xD;
      the same protocol of vitamin D treated patients. All participants will be assessed again&#xD;
      after 24 weeks after vitamin D initiation. Analysis: the investigators will use on-way ANOVA&#xD;
      with repeated measures for comparison of vitamin D and control groups. The investigators will&#xD;
      apply intention to treat and LOCF.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Actual">February 28, 2017</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Positive and Negative Syndrome Scale total score</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the MoCA Cognitive composite score</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Positive and Negative Syndrome Scale sub-scores</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Clozapine Resistant Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Supplementation of Vitamin D as add-on to the regular anti-psychotic treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo as oral drops once weekly as add-on to the regular anti-psychotic treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>once weekly oral drops preparation at a daily dose of 2000 IU X 7 = 14,000 IU per week (about 60 drops each week).</description>
    <arm_group_label>Vitamin D</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females&#xD;
&#xD;
          2. Age 18-65 years&#xD;
&#xD;
          3. Diagnosis of schizophrenia according to DSM-IV-TR criteria, as confirmed by two senior&#xD;
             psychiatrists&#xD;
&#xD;
          4. Total PANSS score &gt; 70&#xD;
&#xD;
          5. CGI-S &gt; 3&#xD;
&#xD;
          6. Clozapine treatment for at least 18 weeks&#xD;
&#xD;
          7. Vitamin D deficiency: plasma 25-OH-Vitamin D &lt;75 nmol/L (20-30 ng/mL)&#xD;
&#xD;
          8. Able to consume oral drops of vitamin-D&#xD;
&#xD;
          9. Able to sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Mental retardation&#xD;
&#xD;
          2. Organic brain disease&#xD;
&#xD;
          3. Known parathyroid disorder&#xD;
&#xD;
          4. Inborn/acquired vitamin D metabolism disorders&#xD;
&#xD;
          5. Patients already treated with vitamin D supplementation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Geha Mental Health Center</name>
      <address>
        <city>Petach-Tikva</city>
        <zip>45000</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>December 4, 2012</study_first_submitted>
  <study_first_submitted_qc>December 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2013</study_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Geha Mental Health Center</investigator_affiliation>
    <investigator_full_name>Amir Krivoy</investigator_full_name>
    <investigator_title>Senior Psychiatrist</investigator_title>
  </responsible_party>
  <keyword>Clozapine</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Vitamin-D</keyword>
  <keyword>Treatment-resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

